

Monthly Portfolio Update

Pioneer Funds – U.S. Fundamental Growth

31 August 2017

EQUITY

COMMENTARY

Market Review

U.S. equities posted mixed results in August, with the S&P 500 returning 0.3%. Growth continued to outperform value as investors rewarded secular growth over cyclical growth. The Russell 1000 Growth Index returned 1.8% vs. -1.2% for the Russell 1000 Value Index.

Six of the eleven sectors in the growth index posted positive results for the month, led by Real Estate (+4%), Information Technology (+4%) and Healthcare (+3%). Energy (-6%) and Financials (-2%) were the worst performing sectors.

Portfolio Review

The Portfolio underperformed the 1.8% return of the Russell 1000 Growth Index. Year-to-date, the Portfolio's return also trails the 19.2% return for the Index.

Year-to-date, the Portfolio's defensive positioning, with an overweight in less cyclical areas such as Consumer Staples and an emphasis on valuation and earnings stability, has significantly detracted from performance relative to the benchmark. However, this positioning is consistent with the Portfolio's philosophy and focus on limiting downside risk, especially when market valuations are high. On a stock specific basis, not owning Facebook due in part to our concerns about its valuation, negatively impacted relative performance by 0.7%. Consumer stocks such as O'Reilly Automotive and Ross Stores also detracted from performance due to concerns about the highly competitive retailing environment and the potential threat from online competitors such as Amazon.

For the month, individual detractors included pharmaceutical company Allergan, which fell despite reporting inline quarterly results due in part to competition concerns regarding its product for treatment of dry eye, Restasis. We believe that

Allergan has a promising pipeline of products in development that could more than offset any decline in sales of Restasis and we have maintained our position in the stock.

Another detractor, leading retail pharmacy chain CVS Health, failed to keep pace with the market due to a lack of earnings growth, the consequence of a loss of a few large client accounts to a competitor. Despite this near-term setback, we believe CVS is well-positioned competitively for the long term and will grow earnings and cash flow over time.

A third detractor, Intercontinental Exchange, a leading operator of commodity and financial product exchanges, declined, despite posting solid quarterly results. We remain confident in the company's secular growth prospects given the increasing use of data analytics in the investment business.

Individual contributors to relative performance in the month included scientific instrument manufacturer Thermo Fisher Scientific, which rose after reporting strong quarterly results. A second contributor to performance, biopharmaceutical company Gilead, increased after announcing an acquisition of Kite Pharma, which has a promising pipeline of cancer immunotherapy products. Investors viewed the acquisition as a positive step in deploying the company's sizeable cash position. Finally, Raytheon increased after reporting strong quarterly results and a positive outlook given increased defence spending globally.

Outlook

While our outlook for global economic growth remains positive, there are significant risks to this outlook, including a tightening of monetary policy by the Federal Reserve, uncertainty relating to U.S. public policies on trade and immigration, and geopolitical risks such as North Korea. For this reason, we continue to favour secular over cyclical growth.

With respect to the equity markets, we remain cautious given that valuations are high by historical standards. In particular, we believe a number of cyclical stocks - especially in the Industrials sector - have performed well in anticipation of higher economic growth in the U.S., which may not occur if Congress fails to enact policies that stimulate economic growth. We also believe the highly valued technology-oriented stocks that have driven the equity markets higher this year could be vulnerable in a market correction. For this reason, we continue to underweight the Technology sector in general and those stocks in particular.

Consistent with our conservative approach to investing and high quality focus, the Portfolio remains overweight in the Healthcare and Consumer sectors. Healthcare stocks are attractive in our view given reasonable valuations, secular growth due to demographics, high returns on capital, and little prospect of a significant change to the healthcare landscape under the new Administration due to political gridlock in Washington, DC. We also remain optimistic about our consumer holdings despite their recent decline given the strength of their business models and their longer-term growth prospects.

While the Portfolio has lagged the benchmark as the markets have moved higher, this performance is consistent with our expectation of how the Portfolio will perform in sharply rising markets driven by stocks with high valuations. We believe the Portfolio's defensive positioning should allow it to capture most of the upside if markets continue to rise while providing downside protection when the markets turn.

Important Information

Unless otherwise stated all information contained in this document is from Amundi Asset Management and is as at 31 August 2017.

Pioneer Funds – U.S. Fundamental Growth is a sub-fund (the "Sub-Fund") of Pioneer Funds (the "Fund"), a fonds commun de placement with several separate sub-funds established under the laws of the Grand Duchy of Luxembourg.

Past performance does not guarantee and is not indicative of future results. Unless otherwise stated, all views expressed are those of Amundi Asset Management. These views are subject to change at any time based on market and other conditions and there can be no assurances that countries, markets or sectors will perform as expected. Investments involve certain risks, including political and currency risks. Investment return and principal value may go down as well as up and could result in the loss of all capital invested. More recent returns may be different than those shown. Please contact your local Amundi Asset Management representative for more current performance results.

This material is not a prospectus and does not constitute an offer to buy or a solicitation to sell any units of the Fund or any services, by or to anyone in any jurisdiction in which such offer or solicitation

would be unlawful or in which the person making such offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make such offer or solicitation. For additional information on the Fund, a free prospectus should be requested from Pioneer Global Investments Limited, a member of the Amundi group, 1 George's Quay Plaza, George's Quay, Dublin 2, Ireland. Call +353 1 480 2000 Fax +353 1 449 5000 or your local Amundi Asset Management sales office.

This information is not for distribution and does not constitute an offer to sell or the solicitation of any offer to buy any securities or services in the United States or in any of its territories or possessions subject to its jurisdiction to or for the benefit of any Restricted U.S. Investor (as defined in the prospectus of the Fund). The Fund has not been registered in the United States under the Investment Company Act of 1940 and units of the Fund are not registered in the United States under the Securities Act of 1933.

This document is not intended for and no reliance can be placed on this document by retail clients, to whom the document should not be provided.

This content of this document is approved by Pioneer Global Investments Limited, a member of the Amundi group ("PGIL"). In the UK, it is directed at professional clients and not at retail clients and it is approved for distribution by PGIL (London Branch), Portland House, 8th Floor, Bressenden Place, London SW1E 5BH. PGIL is authorised and regulated by the Central Bank of Ireland and subject to limited regulation by the Financial Conduct Authority. Details about the extent of our regulation by the Financial Conduct Authority ("FCA") are available from us on request. The Fund is an unregulated collective investment scheme under the UK Financial Services and Markets Act 2000 and therefore does not carry the protection provided by the UK regulatory system.

Amundi Pioneer Distributor, Inc., 60 State Street, Boston, MA 02109 ("APD"), a U.S.-registered broker-dealer, provides marketing services in connection with the distribution of products managed by Amundi Asset Management or its affiliates. APD markets these products to financial intermediaries, both within and outside of the U.S. (in jurisdictions where permitted to do so) for sale to clients who are not United States persons.

For Broker/Dealer Use Only and Not to be Distributed to the Public.

Date of First Use: 13 September 2017.

Doc ID: